Firstly, the strong upregulation of hepatic TXNIP and ARRDC4 by glucose, may contribute to insulin resistance, considering that these two genes are insulin pathway inhibitors that can be activated by the glucose/fructose responsive transcription factor MondoA and thereby contribute to the adverse effects of MondoA on fat accumulation and insulin resistance [73]. The gene discussed is MLXIP; the disease is Insulin resistance.